2023
Characterization and diagnosis spectrum of patients with cerebrospinal fluid pleocytosis
Dyckhoff-Shen S, Bewersdorf J, Teske N, Völk S, Pfister H, Koedel U, Klein M. Characterization and diagnosis spectrum of patients with cerebrospinal fluid pleocytosis. Infection 2023, 52: 219-229. PMID: 37656347, PMCID: PMC10811117, DOI: 10.1007/s15010-023-02087-8.Peer-Reviewed Original ResearchMeSH KeywordsCentral Nervous System InfectionsCerebrospinal FluidHumansLeukocyte CountLeukocytosisMeningitis, BacterialRetrospective StudiesConceptsCerebrospinal fluid pleocytosisCerebrospinal fluid cell countBacterial meningitisCerebrospinal fluidCNS infectionCell countElevated white blood cell countResultsThe most common etiologyMethodsA retrospective cohort studyNeoplastic diseaseAutoimmune CNS diseaseWhite blood cell countRetrospective cohort studySpectrum of patientsCharacteristics of patientsBlood cell countCerebrospinal fluid proteinAbnormal mental statusLaboratory featuresCSF pleocytosisCSF leukocytesLaboratory parametersClinical presentationNuchal rigidityCommon etiologies
2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study
Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia 2020, 34: 3149-3160. PMID: 32132655, PMCID: PMC8155811, DOI: 10.1038/s41375-020-0783-3.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaOverall survivalMyeloid leukemiaMultivariate analysisLong-term clinical outcomesComposite complete remissionImpact of leukapheresisManagement of hyperleukocytosisMedian overall survivalThirty-day mortalityHigh-quality evidenceWhite cell countProportional hazards modelUse of leukapheresisLogistic regression modelsSignificant resource useIntensive chemotherapyComplete remissionHazard ratioClinical outcomesInferior outcomesUnadjusted analysesQuality evidencePotential complicationsOdds ratio